This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead to Start Studies for an Inhaled Version of Remdesivir
by Zacks Equity Research
Gilead (GILD) announces plans to start studies for an inhaled version of the experimental candidate, remdesivir, in August.
Nasdaq's Excels in Weekly Performance: 5 Best Stocks in ETF
by Sweta Killa
In a tug of war between bulls and bears, the Dow Jones and S&P 500 gained at least 1% each last week while the Nasdaq Composite Index advanced over 3%.
Incyte (INCY) Looks Good: Stock Adds 8.3% in Session
by Zacks Equity Research
Incyte (INCY) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Alpine Skyrockets on License Deal With AbbVie for ALPN-101
by Zacks Equity Research
Alpine (ALPN) signs an agreement with AbbVie granting exclusive worldwide option and license to its pipeline candidate, ALPN-101. The deal significantly boosts Alpine's funds.
Regeneron Initiates Study on Antibody Cocktail for Coronavirus
by Zacks Equity Research
Regeneron (REGN) initiates study on its antibody cocktail, REGN-COV2, for the prevention and treatment of COVID-19.
Why Is Incyte (INCY) Up 2.9% Since Last Earnings Report?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead Down on Mixed Results From Coronavirus Drug Remdesivir
by Zacks Equity Research
Gilead's (GILD) shares decline on mixed results from a late-stage study on coronavirus drug.
Roche Starts Study on Actemra with Gilead's Drug for Coronavirus
by Zacks Equity Research
Roche (RHHBY) commences a phase III study on Actemra with Gilead's remdesivir in hospitalized patients with severe COVID-19 pneumonia.
PhaseBio Gets FDA Nod to Begin Study for Coronavirus Treatment
by Zacks.com
PhaseBio (PHAS) receives clearance of IND application from the FDA to evaluate PB1046 as a treatment for hospitalized COVID-19 patients.
Incyte, MorphoSys Application for Lymphoma Drug Validated
by Zacks Equity Research
Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.
Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More
by Zacks Equity Research
The biotech sector remains in focus with pipeline updates on coronavirus treatments.
Acceleron (XLRN) Q1 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Acceleron (XLRN) posts a wider-than-expected Q1 loss due to increased operating expenses. The company misses on revenues as well.
Mallinckrodt (MNK) Q1 Earnings Beat Estimates, Sales Miss
by Zacks Equity Research
Mallinckrodt (MNK) declines on sales miss in the first quarter and a challenging outlook for the remainder of the year despite reporting an earnings beat.
Alexion (ALXN) Beats on Q1 Earnings & Sales, Lowers Guidance
by Zacks Equity Research
Alexion (ALXN) beats on earnings and sales in the first quarter of 2020 but lowers view due to the ongoing pandemic.
Company News for May 6, 2020
by Zacks Equity Research
Companies in the news are: LITE, ITW, INCY, PTLA
Incyte (INCY) Misses Q1 Earnings Estimates, Beats on Revenues
by Zacks Equity Research
Incyte (INCY) misses on first-quarter earnings due to an upfront payment made in March related to a collaboration agreement. Sales beat on strong Jakafi growth.
Incyte (INCY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of -3675.00% and 4.03%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Remdesivir Gets Emergency Approval: What's In Store for Gilead?
by Zacks Equity Research
In a short span of time, Gilead's Remdesivir has been successful in treating some coronavirus patients. But will this give a boost to the pharmaceutical giant?
Gilead (GILD) Q1 Earnings Top, Coronavirus Candidate in Focus
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the first quarter but the uncertain outlook for the year dampens investors' hopes.
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports first-quarter 2020 results.
Analysts Estimate Incyte (INCY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novartis (NVS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Novartis (NVS) reports strong results for the first quarter, driven by solid performance from key drugs and forward purchasing due to COVID-19.
Focus on Coronavirus Treatments to Boost Biotech Stocks
by Zacks Equity Research
With the coronavirus pandemic raging on, biotech companies are in focus as they are racing against time to evaluate every possible therapy to combat the spread.
Factors Setting the Tone for Novartis' (NVS) Q1 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with the impact of the coronavirus pandemic on its outlook when Novartis (NVS) reports first-quarter 2020 results.
Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.